TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05517863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser therapy
Description: All patients received 2 sessions of laser therapy / week in two consecutive months of treatment aiming complete wound closure , patients received \& infrared laser therapy plus traditional wound care:~(I) Use red \& infrared laser therapy device with 4 different wavelengths in a synchronized mode:~1. 980 nm for wound decontamination, improve circulation, lymphatic drainage~2. 915 nm enhances O2 delivery~3. 810 nm increases ATP production~4. 650 nm accelerate surface healing, tissue regeneration plus traditional wound treatment mentioned before

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser therapy
Description: All patients received 2 sessions of laser therapy / week in two consecutive months of treatment aiming complete wound closure , patients received \& infrared laser therapy plus traditional wound care:~(I) Use red \& infrared laser therapy device with 4 different wavelengths in a synchronized mode:~1. 980 nm for wound decontamination, improve circulation, lymphatic drainage~2. 915 nm enhances O2 delivery~3. 810 nm increases ATP production~4. 650 nm accelerate surface healing, tissue regeneration plus traditional wound treatment mentioned before

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser therapy
Description: All patients received 2 sessions of laser therapy / week in two consecutive months of treatment aiming complete wound closure , patients received \& infrared laser therapy plus traditional wound care:~(I) Use red \& infrared laser therapy device with 4 different wavelengths in a synchronized mode:~1. 980 nm for wound decontamination, improve circulation, lymphatic drainage~2. 915 nm enhances O2 delivery~3. 810 nm increases ATP production~4. 650 nm accelerate surface healing, tissue regeneration plus traditional wound treatment mentioned before
Study: NCT05598463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OASIS Pro
Description: This device can track the joint movement and provide real-time feedback on the exercise performance and accuracy using Kinect camera sensor, and Wearable sensor (IMU). This device is connected to the website, which available for medical staff prescribe the exercise protocol and monitor individual exercise adherence.
Study: NCT04580524

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repair of ventral hernia using biologic mesh
Description: Ventral hernia will be repaired using biologic mesh

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repair of ventral hernia using suture repair or synthetic mesh
Description: Ventral hernia will be repaired using the current treatment methods
Study: NCT05264766

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling helmet on
Description: Cooling helmet with circulating cold water

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cooling helmet off
Description: Cooling helmet without circulating cold water
Study: NCT05765045

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nursing triage protocol
Description: Medically approved and supervised standing order that allows trained ER nurses to start medical imaging (RX) for adult patients with minor traumata to the limbs.
Study: NCT04765189

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product is 100% maltodextrin. Daily dosage is 500 mg in 2 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum A
Description: Verum A is 200 mg of mangosteen extract. Daily dosage is 200 mg in 2 capsules.
Study: NCT04329104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-MALMAB0100-00-AB (CIS43LS)
Description: Administered via one-time IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-MALMAB0100-00-AB (CIS43LS)
Description: Administered via one-time IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-MALMAB0100-00-AB (CIS43LS)
Description: Administered via one-time IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-MALMAB0100-00-AB (CIS43LS)
Description: Administered via one-time IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-MALMAB0100-00-AB (CIS43LS)
Description: Administered via one-time IV infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Administered via one-time IV infusion
Study: NCT05952505

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 vaccine coadministered with vricella vaccine
Description: Subjects will be coadministered with inactivated SARS-CoV-2 vaccine and varicella vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 vaccine coadministered with MMR
Description: Subjects will be coadministered with SARS-CoV-2 vaccine and MMR.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated SARS-CoV-2 vaccine administered alone
Description: Subjects will be immunized with inactivated SARS-CoV-2 vaccine alone
Study: NCT06072352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perineal cleansing using chlorhexidine acetate solution
Description: Perineal cleansing using chlorhexidine acetate solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Perineal cleansing using normal saline
Study: NCT04765189

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum B
Description: Verum B is 400 mg of mangosteen extract. Daily dosage is 400 mg in 2 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum C
Description: Verum C is 200 mg mangosteen extract + 300 mg grape extract. Daily dosage is 500 mg in 2 capsules.
Study: NCT06170840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QY101Placebo/QY101 ointment
Description: External use for BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QY101Placebo/QY101 ointment
Description: External use for BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QY101Placebo/QY101 ointment
Description: External use for BID
Study: NCT06680089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]RCCB6
Description: Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]RCCB6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]RCCB6 injection.
Study: NCT05510102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WHOOP strap 4.0 (full data access)
Description: The WHOOP strap 4.0 provides continuous physiologic data via remote monitoring. Subjects will have full remote monitoring data access throughout the entirety of the study (6 months).
Study: NCT06692166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW2821
Description: 1.25mg/kg of 9MW2821 by intravenous infusion on days 1, 8 and 15 of every 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: 1.0 or 1.25 mg/m \^2 topotecan by intravenous infusion on days 1 to 5 or 1000 mg/m \^2 gemcitabine by intravenous infusion on days 1 and 8 or 500 mg/m \^2 pemetrexed by intravenous infusion on day 1 of every 21 days
Study: NCT06697977

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phytosterols
Description: 2 grams of phytosterols given as 7 pills per day
Study: NCT05510102

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WHOOP strap 4.0 (partial data access)
Description: The WHOOP strap 4.0 provides continuous physiologic data via remote monitoring. Subjects will be blinded to remote monitoring data for the first 3 months of the study followed by an unblinding and full access to remote monitoring data at the 3 month mark (continued for the remainder of the study).
Study: NCT06697977

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 7 pills per day
Study: NCT06702033

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: IMRT or IMPT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: IMRT or IMPT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: IMRT or IMPT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: IMRT or IMPT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Dose of 100 mg/m\^2 IVPB over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Dose of 100 mg/m\^2 IVPB over 60 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Standard of care
Study: NCT06701227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In Situ Simulation
Description: The simulation scenario included briefing (5 min), scenario (10 min), and debriefing (20 min).~Materials and Simulators: neonatal mannequin, with its crying controlled by a smartphone; breastfeeding simulator that had the function of ejecting liquid imitating human milk.~Team: One facilitator and one actor playing a Community Health Worker.
Study: NCT06703411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose IV
Description: IV iron sucrose 200mg per visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy
Description: Standard of care (HFrEF 4 pillars treatment)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: Standard of care (HFrEF 4 pillars treatment)
Study: NCT06704113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meloxicam 7,5mg
Description: Comparison of analgesic efficacy of Meloxicam Vs Ibuprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meloxicam 7,5mg
Description: Comparison of analgesic efficacy of Meloxicam Vs Ibuprofen
Study: NCT06703814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative flow-controlled ventilation strategy
Description: In the FCV group, intraoperative ventilation will be provided with the EVONE (IES Ventinova Medical).PEEP and Ppeak are titrated guided by dynamic compliance, as follows: Starting from a default setting of 5 cmH2O of PEEP and 15 cmH2O of Ppeak, PEEP and Ppeak are equally increased by 1 cmH2O steps and the PEEP value with the highest VT and thus highest dynamic compliance is defined as best PEEP. Subsequently, Ppeak is stepwise (+1 cmH2O) increased until there is no further over-proportional increase in tidal volume (VT) (i.e. measured VT \> expected VT according to measured dynamic compliance), defined as best driving pressure. No recruitment maneuvers are carried out during FCV. With the I:E ratio set to 1:1, flow is adjusted to establish normocapnia (target etCO2 4.5 to 5.8 kPa). FiO2 is adjusted to maintain oxygen saturation (SpO2) \> 92%.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative pressure-controlled ventilation strategy
Description: In the PCV group, intraoperative ventilation will be provided by a standard anesthesia ventilator in use in the respective participating centers. Patients will be ventilated in PCV mode, at the lowest inspired oxygen fraction (FiO2), to maintain oxygen saturation (SpO2) \> 92%. It is left to the discretion of the attending anesthesiologist to use a higher fraction of FiO2. Inspiratory to expiratory ratio is set at 1:1 to 1:2, respiratory rate will be adjusted to target normocapnia (target etCO2 4.5 to 5.8 kPa. VT will be set at 7 to 9 ml/kg predicted body weight (PBW). The PBW is calculated according to a predefined formula: 50 + 0.91 x (centimeters of height - 152.4) for males and 45.5 + 0.91 x (centimeters of height - 152.4) for females. Ventilation starts with 5 cm H2O PEEP, and can be increased to 10 cm H2O PEEP.
Study: NCT06703905

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expanded pancreaticoduodenectomy surgery
Description: Traditional minimally invasive pancreaticoduodenectomy combined with the TRIANGLE procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticoduodenectomy
Description: Traditional minimally invasive pancreaticoduodenectomy
Study: NCT06702852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS imaging in addition to SOC
Description: The intervention group will receive the standard of care per the facility Standard Operating Procedures (SOP) with the addition of NIRS imaging utilizing the SnapshotNIR
Study: NCT06195267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sivelestat
Description: The total 24-hour dose of Sivelestat sodium (4.8mg/kg) was dissolved with 50 ml normal saline. The drug flow rate was set at 2ml/h with an intravenous microinfusion pump, and the constant speed infusion was completed in 24h.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Blank control
Description: Patients only received standard treatment and care.
Study: NCT05824975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI-102 subcutaneous (SC)
Description: 0.12 mg/kg, 0.24 mg/kg or Recommended phase 2 dose of GI-102 will be administered via SC injection Q3W up to 2 years (approximately 35 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI-102
Description: Dose level will be escalated from 0.06 mg/kg to 0.45 mg/kg and Recommended phase 2 dose (or RP2D-1, RP2D+1) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Doxorubicin will be administered intravenously at a dose of 75 mg/m2 on Day 3 every 3-week (21-day) cycle for up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel will be administered intravenously over 1 hour at a dose of 80 mg/m2 each time weekly as a diluted solution according to the prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin
Description: Eribulin will be administered intravenously at a dose of over 1.4 mg/m2 over 2 to 5 minutes on Days 3 and 10 every 3-week (21-day) cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab deruxtecan (T-DXd)
Description: T-DXd will be administered initially as a 5.4 mg/kg (or 6.4 mg/kg only for gastric cancer) IV over 30 - 90 minutes every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI-102
Description: Recommended phase 2 dose (or RP2D-1, RP2D-2) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI-102
Description: Recommended phase 2 dose (or RP2D-1, RP2D-2) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI-102
Description: Recommended phase 2 dose (or RP2D-1, RP2D-2) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI-102
Description: Recommended phase 2 dose (or RP2D-1, RP2D-2) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI-102
Description: Recommended phase 2 dose (or RP2D-1, RP2D-2) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
Study: NCT06122571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ConcenTrace
Description: The product contains concentrated seawater from Utah's inland sea.
Study: NCT05941299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REGENERA breast implant implantation
Description: Each patient will perform 13 study visits, and at each visit, all necessary study procedures will be performed according to the clinical investigation plan:~* Screening~* Pre-surgery treatment~* Surgery and study device implant~* Post-surgery follow-up
Study: NCT03716999

Intervention type: OTHER
Intervention: Starlight Therapy
Description: Starlight Projector will be placed in patients' rooms and project starlight on the ceilings and walls in an effort to reduce unpleasant symptoms
Study: NCT06374121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PerSorb cartridge (CytoSorbents Europe GmbH, Germany)
Description: This is a highly bio-/hemo-compatible, low-flow resistance polymer cartridge able to remove cytokines and other inflammatory mediators via adsorption.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PerLife PerKidney
Description: The system for ex vivo kidney reconditioning (Aferetica, Italy), which allows hypothermic oxygenated pulsatile perfusion of the organ.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PerLife PerKidney
Description: The system for ex vivo kidney reconditioning (Aferetica, Italy), which allows hypothermic oxygenated pulsatile perfusion of the organ.
Study: NCT05947448

Intervention type: DRUG
Intervention: Azilsartan Medoxomil Potassium Tablet
Description: Azilsartan Medoxomil Potassium Tablet，80mg，qd，lasts six month
Study: NCT06401642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant
Description: 10 mg intranasal
Study: NCT04767022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Coated PTCA Balloon Catheter(Genoss® DCB)
Description: Drug Coated Balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel Coated PTCA Balloon Catheter(SeQuent® Please NEO)
Description: Drug Coated Balloon
Study: NCT05617625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 0.8 mg/kg q6h x 12 doses via IV injection on Days -9, -8, and -7 prior to transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70 mg/m\^2/day x 2 days via IV infusion over 30 minutes on Days -6 and -5 prior to transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/days x 5 days via IV infusion over 30 minutes on Days -6, -5, -4, -3, and -2 prior to transplant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)
Description: CliniMACS system will be used to derive CD34+ enriched, T-cell depleted (T-cells limited to 1.0 x 10\^5 CD3+ cells/kg) PBSC for transplant, which will occur on Day 0. PBSC (5 x 10\^6 CD34+ cells/kg) are suspended in a volume of approximately 20-50 mL and delivered via IV infusion over 15 minutes.
Study: NCT05751928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-217
Description: BCD-217 (anti-CTLA4 agent nurulimab + anti-PD1) once every 3 weeks in the neoadjuvant setting

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-217
Description: BCD-217 (anti-CTLA4 agent nurulimab + anti-PD1) once every 3 weeks in the neoadjuvant setting

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-PD1
Description: anti-PD1 agent in the adjuvant setting

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-PD1
Description: anti-PD1 agent in the adjuvant setting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Excision of the primary lesion
Description: Excision of the primary lesion will be performed per standard of care.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excision of the primary lesion
Description: Excision of the primary lesion will be performed per standard of care.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excision of the primary lesion
Description: Excision of the primary lesion will be performed per standard of care.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional lymphadenectomy
Description: Regional lymphadenectomy will be performed per standard of care.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional lymphadenectomy
Description: Regional lymphadenectomy will be performed per standard of care.
Study: NCT05202600

Intervention type: PROCEDURE
Intervention: Appendectomy
Description: Surgical removal of the vermiform appendix.

Intervention type: PROCEDURE
Intervention: Appendectomy
Description: Surgical removal of the vermiform appendix.
Study: NCT05947448

Intervention type: DRUG
Intervention: Azilsartan Medoxomil Potassium Tablet
Description: Azilsartan Medoxomil Potassium Tablet，80mg，qd，lasts six month

Intervention type: DRUG
Intervention: Nifedipine Sustained -release Tablets
Description: Nifedipine Sustained -release Tablets，qd，The maximum clinical dose，lasts six months；

Intervention type: DRUG
Intervention: Nifedipine Sustained -release Tablets
Description: Nifedipine Sustained -release Tablets，qd，The maximum clinical dose，lasts six months；

Intervention type: DRUG
Intervention: Levoamlodipine Maleate Table
Description: Levoamlodipine Maleate Table，qd，The maximum clinical dose，lasts six months；

Intervention type: DRUG
Intervention: Levoamlodipine Maleate Table
Description: Levoamlodipine Maleate Table，qd，The maximum clinical dose，lasts six months；
Study: NCT06244784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: effectiveness of a training course on a healthy work environment for nurses and nursing assistants in a hospital
Description: Once the participants have been included in the study, they will be assigned to each group; control group and intervention group by convenience sampling. Baseline data will be collected in both groups. At this time, questionnaires will be collected in both populations and focus groups will be conducted in the professionals assigned to both groups. Once the data have been obtained, the intervention group will conduct the training course.~After the training, data will be collected again at three different times: 1) Right after the training: questionnaires and focus group will be collected from intervention group professionals; 2) 6 months after the training: questionnaires will be collected from control group and intervention group; 3) 12 months after the training: questionnaires will be collected and focus groups will be conducted in both groups.
Study: NCT06077006

Intervention type: OTHER
Intervention: questionnaires Only
Description: questionnaires Only

Intervention type: OTHER
Intervention: questionnaires Only
Description: questionnaires Only